Childhood Ependymoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood ependymoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus
Childhood Ependymoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment of Newly Diagnosed Childhood Subependymoma
In the newly diagnosed patient, careful evaluation to fully determine the extent of disease must precede the treatment of ependymoma. Surgery should be performed in an attempt at maximal tumor reduction; children have improved progression-free survival (PFS) if there is minimal residual disease present after surgery.[1,2] Postoperatively, magnetic resonance imaging (MRI) should be performed to determine the extent of resection, although the rate of dissemination is low. If not performed preoperatively, MRI of the entire neuraxis should be obtained to evaluate for disease dissemination. Myxopapillary ependymomas, considered to be a benign histologic subtype of ependymoma, have a relatively high incidence of central nervous system (CNS) tumor dissemination at diagnosis and at follow-up, and require imaging of the complete cranial spinal axis at the time of diagnosis and during follow-up.[3,4] Patients with residual tumor or disseminated disease should be considered at high risk for
Childhood Ependymoma Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Childhood Brain Stem Glioma
Childhood brain stem glioma is a disease in which benign (noncancer) or malignant (cancer) cells form in the tissues of the brain stem. The brain stem is the part of the brain connected to the spinal cord. It is located in the lowest part of the brain,just above the back of the neck. The brain stem is the part of the brain that controls breathing,heart rate,and nerves and muscles used in ...
Childhood Ependymoma Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000062761-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Brain Stem Glioma Treatment
Childhood Brain Stem Glioma Treatment (PDQ®): Treatment - Patient Information [NCI] - Thyrotropin-Producing Tumors Treatment
Standard Treatment Options for Thyrotropin-Producing TumorsStandard treatment options for thyrotropin-producing tumors include the following:Surgery (usually a transsphenoidal approach), with or without adjuvant radiation therapy.[1,2] Somatostatin analogues, such as octreotide.[3,4]Transsphenoidal surgery is the treatment of choice for patients with thyrotropic adenomas. Adjuvant radiation therapy may be employed when surgery is known to be noncurative even if the patient is still euthyroid because relapse is inevitable, and the full effect of radiation therapy requires months or years. Medical therapy may be required for patients who still have hyperthyroid symptoms despite surgery and external radiation. Somatostatin analogues are the drugs of choice for treatment; however, the efficacy of treatment may wane with time.[1,2,3,4]Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with pituitary tumor. The
Important It is possible that the main title of the report Meningioma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Childhood Ependymoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (02 / 06 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Evidence of BenefitAdded text about a study that compared neuroblastoma incidence and mortality rates in Japan in three cohorts: children born before screening between 1980 and 1983, and those born during screening between 1986 and 1989, and between 1990 and 1998 (cited Hiyama et al. as reference 32).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Childhood Ependymoma Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Neuroblastoma Screening (PDQ®): Screening - Patient Information [NCI] - Growth Hormone-Producing Pituitary Tumors Treatment
Standard Treatment Options for Growth Hormone (GH)-Producing Pituitary TumorsStandard treatment options for GH-producing pituitary tumors include the following:Surgery (usually a transsphenoidal approach).Dopamine analogues, such as bromocriptine.Somatostatin analogues, such as octreotide. The GH-receptor antagonist, pegvisomant.[1,2]Surgery and postoperative radiation therapy.Treatment for patients with acromegaly includes surgical, radiation, and medical therapies. Treatment will depend on the size and extent of the tumor and the need for rapid cessation of hormone function that results in serious clinical sequelae (i.e., hypertension and cardiomyopathy). Microadenomectomy or macroadenoma decompression is approached transsphenoidally in most patients. Increasingly, endoscopic surgery is used to allow the entire surgical field to be viewed and to allow tumor tissue that would otherwise be inaccessible with rigid instruments to be safely resected. Complete return of GH
Childhood Ependymoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Stage Information for Pituitary Tumors
As with other tumors of the central nervous system (CNS), no tumor, nodes, metastases-based American Joint Committee on Cancer classification and staging system for pituitary tumors exists. Pituitary tumors are classified according to size and divided into microadenomas (i.e., the greatest diameter is <10 mm) and macroadenomas (i.e., the greatest diameter is ≥I0 mm). Most pituitary adenomas are microadenomas. The most widely used radioanatomical classification was based primarily on a neuroradiological examination including skull x-rays, pneumoencephalography, polytomography, and carotid angiography. Subsequently validated by the application of more accurate magnetic resonance imaging (MRI) and computed tomography, this radioanatomical classification places adenomas into 1 of 4 grades (I–IV) and has been augmented by additional studies including immunohistochemistry and electron microscopy. Currently, MRI is considered the imaging modality of choice for the diagnosis